OA05.05 Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Refractory SCLC: A Subgroup Analysis of a Phase 1/2 Study
2023; Elsevier BV; Volume: 18; Issue: 11 Linguagem: Inglês
10.1016/j.jtho.2023.09.042
ISSN1556-1380
AutoresMelissa L. Johnson, Mark M. Awad, T. Koyama, Martin Gutierrez, G.S. Falchook, Sarina A. Piha‐Paul, Toshihiko Doi, Toru Satoh, Nobuhiko Okamoto, Jasveer Singh, N. Yoshizuka, M. Qian, Xiaozhong Qian, Brittany P. Tran, O. Dosunmu, Rastislav Mucha, Hillarie Plessner Windish, Manish R. Patel,
Tópico(s)Nanoparticle-Based Drug Delivery
ResumoB7 homolog 3 (B7-H3), a transmembrane immunoregulatory protein is overexpressed in several tumor types including small-cell lung cancer (SCLC). Among patients with SCLC, 65% have moderate-to-high expression of B7-H3. I-DXd is a novel B7-H3-directed antibody-drug conjugate that leverages the clinically validated deruxtecan (DXd) technology, with a plasma-stable linker and potent topoisomerase I inhibitor payload, to enhance selective tumor cell death and reduce systemic exposure of the payload. We conducted a phase 1/2 trial of heavily pretreated patients with advanced solid tumors evaluating I-DXd (Doi et al.
Referência(s)